Given that CK2 is overexpressed in cancer [37] and exerts protumoral effects by downregulating tumor suppressors [44, 45], we assessed whether pharmacological inhibition of CK2 via Silmitasertib increases endogenous SALL2 protein levels in different cancer cell lines. Here, SALL2 is linked to cancer.